非手术石膏固定与手术复位治疗儿童严重移位桡骨远端骨折(CRAFFT研究):一项多中心、随机、对照非劣效性试验及经济学评价
CRAFFT是一项在49家英国医院开展的多中心、随机、非劣效性试验,纳入750例4-10岁严重移位桡骨远端骨折患儿,随机分为非手术石膏固定组(375例)和手术复位组(375例)。主要终点为3个月时PROMIS上肢功能评分,非手术组平均44.9(SD 8.7),手术组46.6(8.8),校正均数差-1.64(95%CI -2.84至-0.44),置信区间偏向手术复位且超出预设非劣效界值-2.5分,未证明非劣效性。完全离断骨折亚组结果与更宽的非劣效界值一致。手术组8周内并发症更多,包括压伤2例、伤口感染6例、瘢痕5例、神经刺激1例;12个月随访再骨折13例(非手术组9例,手术组4例)。非手术石膏固定每位患者平均节省费用1665英镑(95%CI 1487至1843),QALYs边际减少0.023(95%CI -0.037至-0.009),在每QALY 20000英镑和30000英镑阈值下具有成本效益的概率均为100%。作者认为手术复位的功能优势小、低于家庭认为有意义的阈值且不持久,支持多数患儿考虑石膏优先策略。
要点
- 3个月时PROMIS上肢功能评分非手术石膏组44.9(SD 8.7) vs 手术复位组46.6(8.8),校正均数差-1.64(95%CI -2.84至-0.44),未达预设非劣效界值-2.5分。
- 完全离断骨折亚组(329例,44%)结果与更宽的非劣效界值一致。
- 手术复位组8周内并发症更多:压伤2例、伤口感染6例、瘢痕5例、神经刺激1例;12个月再骨折非手术组9例 vs 手术组4例。
- 非手术石膏固定平均每人节省1665英镑(95%CI 1487至1843),QALYs边际减少0.023(95%CI -0.037至-0.009),在20000和30000英镑/QALY阈值下成本效益概率均为100%。
- 作者认为手术复位的功能优势小、低于家庭认为有意义的阈值且不持久,支持多数患儿考虑石膏优先策略。
适用人群与场景
- 年龄4-10岁、严重移位桡骨远端骨折的儿童,来自英国49家提供急性儿科创伤治疗的二级或三级医院。
- 排除标准:54例符合排除标准;423例未进入研究,多数因临床或家长方面缺乏均势。
诊断标准与关键阈值
- 非劣效性界值:主要试验人群预设为-2.5分(PROMIS上肢功能评分)。
- 完全离断骨折亚组预设更宽的非劣效界值-5分。
- 主要终点:3个月时PROMIS上肢功能评分(患者报告结局测量信息系统上肢功能评分)。
处置流程与药物剂量
- 非手术石膏固定:不使用全身麻醉或镇静,不对骨折位置进行有意手法复位,以石膏管型固定骨折;不推荐随机化后固定超过6周。
- 手术复位:在全身麻醉或清醒镇静下恢复解剖对线,固定与否由外科医生酌情决定。
研究设计与关键结果
- 多中心、随机、非劣效性试验,49家英国医院,750例患儿随机分配(非手术石膏组375例,手术复位组375例);男性456例(61%),女性294例(39%),中位年龄7.9岁(IQR 6.5-9.5);完全离断骨折329例(44%);主要终点数据来自640例(85%)。
- 3个月时PROMIS上肢功能评分:非手术石膏组平均44.9(SD 8.7) vs 手术复位组46.6(8.8),校正均数差-1.64(95%CI -2.84至-0.44),置信区间偏向手术复位且超出预设非劣效界值-2.5分。
- 完全离断骨折亚组结果与更宽的非劣效界值-5分一致。
- 8周内大多数并发症发生在手术复位组:压伤2例、伤口感染6例、瘢痕5例、神经刺激1例。
- 12个月随访期间再骨折13例(非手术石膏固定后9例,手术复位后4例)。
- 经济学评价(NHS和个人社会服务视角,12个月):非手术石膏固定每位患者平均费用减少1665英镑(95%CI 1487至1843),QALYs边际减少0.023(95%CI -0.037至-0.009);在每QALY 20000英镑和30000英镑阈值下,非手术石膏固定具有成本效益的概率均为100%。
证据类型、等级与局限
- 证据类型:多中心、随机、对照、非劣效性试验及经济学评价。
- 非劣效性界值:主要试验人群-2.5分;完全离断骨折亚组-5分。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,手术复位的功能优势小、低于家庭认为有意义的阈值且不持久,支持多数患儿考虑石膏优先策略。
- 手术复位与更高费用、早期操作并发症相关,仅带来适度的外观改善。
- 非手术石膏固定不使用全身麻醉或镇静,不对骨折位置进行有意手法复位;不推荐随机化后固定超过6周。
指南或共识出处
- CRAFFT研究(Children's Radius Acute Fracture Fixation Trial),ISRCTN10931294,由英国国家卫生与 care 研究协会(NIHR)健康技术评估项目(17/22/02)和NIHR牛津生物医学研究中心资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Severely displaced distal radial fractures are among the most common and controversial injuries in children. Despite observational evidence of reliable remodelling with growth in younger children, their alarming radiographic appearance-particularly when completely displaced (off-ended)-has driven routine surgical reduction and fixation. The Children's Radius Acute Fracture Fixation Trial (CRAFFT) aimed to evaluate the clinical and cost-effectiveness of surgical reduction compared with non-surgical casting.
METHODS: This pragmatic, multicentre, randomised, non-inferiority trial included participants (aged 4-10 years) with a severely displaced distal radial fracture from 49 hospitals in the UK. Recruiting centres were secondary or tertiary care hospitals providing acute paediatric trauma care. Participants were randomly assigned to either non-surgical casting or surgical reduction, using a minimisation algorithm with a random element and stratification factors were centre, age group, fracture location, and displacement severity. Participants and their parents and carers could not be masked to treatment. Surgical reduction was performed under general anaesthesia or conscious sedation, to restore anatomical alignment, with fixation permitted at the discretion of the surgeon. Non-surgical care involved immobilisation of the fracture in a plaster cast without general anaesthesia or sedation, and without purposeful manipulation of the fracture position. Immobilisation of the fracture beyond 6 weeks post-randomisation was not recommended. The primary outcome was upper limb function at 3 months, measured using the Patient Report Outcomes Measurement System (PROMIS) Upper Extremity Score for Children in the intention-to-treat population, which included all participants in the groups to which they were randomly assigned, irrespective of treatment received. The non-inferiority margin was conservatively set at -2·5 points for the main trial population. A prespecified subgroup analysis was powered to assess whether non-surgical casting could exclude a larger more clinically relevant margin of -5 points among children with completely off-ended fractures. Complications and serious adverse events were summarised in a safety (as-treated) population defined by treatment received. A within-trial economic evaluation was undertaken from the perspective of the UK National Health Service (NHS) and Personal Social Services over a 12-month time period. The trial was registered with the ISRCTN registry, ISRCTN10931294, recruitment is complete and extended follow-up to 3-years post-randomisation is ongoing.
FINDINGS: Between Aug 11, 2020, and May 30, 2024, 1227 children were screened for eligibility across 49 UK hospitals. 477 children were excluded (54 met exclusion criteria and 423 did not enter the study, the majority for lack of clinical or parental equipoise). 750 participants were randomly assigned, 375 to the non-surgical casting group and 375 to the surgical reduction group. 456 (61%) participants were male, 294 (39%) were female, and the median age of participants was 7·9 years (IQR 6·5-9·5). 329 (44%) of the 750 participants had completely off-ended fractures. Primary outcome data were collected from 640 (85%) participants. At 3 months post-randomisation, the mean PROMIS Upper Extremity score was 44·9 (SD 8·7) in the non-surgical casting group and 46·6 (8·8) in the surgical reduction group (adjusted mean difference -1·64 [95% CI -2·84 to -0·44]), with the confidence interval favouring surgical reduction but extending beyond the prespecified non-inferiority margin of -2·5 points. In children with completely off-ended fractures, findings were consistent with non-inferiority against the wider, prespecified margin for this group. Most complications within 8 weeks occurred in the surgical reduction group, including pressure damage (n=2), wound infections (n=6), scarring (n=5), and nerve irritation (n=1). During the 12-months of follow-up, refracture occurred in 13 participants (nine after non-surgical casting and four after surgical reduction). From an NHS and Personal Social Services perspective, non-surgical casting was associated with a significant reduction in mean cost per patient of £1665 (95% CI 1487 to 1843) and a marginal incremental reduction in quality-adjusted life-years (QALYs; -0·023 [95% CI -0·037 to -0·009]). The probability of non-surgical casting being cost-effective at the £20 000 and £30 000 per QALY threshold was 100%, indicating that the small short-term functional advantage of surgical reduction was not cost-effective.
INTERPRETATION: The CRAFFT trial did not demonstrate non-inferiority of non-surgical casting at 3 months against a conservative margin; however, the observed difference in favour of surgical reduction was small, below thresholds that families considered meaningful, and did not persist beyond early recovery. Surgical reduction was associated with higher costs, early procedural complications, and only a modest improvement in cosmetic appearance, supporting consideration of a cast-first strategy for most children.
FUNDING: National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (17/22/02) and the NIHR Oxford Biomedical Research Centre.
参考来源
- Perry DC, Zimmermann A, Achten J, et al. Non-surgical casting versus surgical reduction for children with severely displaced distal radial fractures (the CRAFFT Study): a multicentre, randomised, controlled non-inferiority trial and economic evaluation. Lancet. 2026. PMID: 41965242. doi:10.1016/S0140-6736(26)00409-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。